AI NewsWistron opened its first U.S. manufacturing plant in Fort Worth, Texas — a 324,000-square-foot greenfield facility producing superchips used in NVIDIA AI systems.
AI NewsA projection indicates data centers could quadruple their electricity consumption by 2035, with new facilities built through 2033 potentially using as much power as India does today.
AI NewsOpenAI has introduced a ChatGPT for Small Businesses program aimed at helping entrepreneurs develop AI skills, automate work, and grow with ChatGPT Work.
AI NewsNVIDIA has announced Spectrum-6, a networking milestone built for Vera Rubin and aimed at gigascale AI factories connecting hundreds of thousands of GPUs and CPUs.
AI NewsGoogle introduced Gemini 3.5 Flash Cyber, a lower-cost AI security model for detecting and fixing vulnerabilities, positioned against larger systems like Anthropic's Mythos.
AI NewsHalliday's second-generation smart glasses replace the criticized movable display window from the original with a more conventional design that a reviewer found improved.
AI NewsCouchbase adopted Amazon Bedrock with Anthropic's Claude models to power Capella iQ, using a multi-model architecture and reporting operational benefits in production.
AI NewsTradeshift deployed Amazon Quick with agentic AI to replace its legacy business intelligence tool, reporting up to 30x faster query responses and a 40% reduction in total cost of ownership.
AI NewsBristol Myers Squibb announced it will deploy a second NVIDIA DGX SuperPOD, built on NVIDIA Vera Rubin, to expand one of the largest AI clusters in life sciences.
Use CasesAccounting is an unusually good fit for AI on the input side and an unusually bad one on the output side. The line between those two is the whole discipline.
Use CasesContent moderation is automation by necessity, not by choice — the volume leaves no alternative. Here is what classifiers genuinely catch, what context defeats, and the transparency the EU's DSA now requires.
Use CasesDrug discovery is the most scientifically credible AI use case — and the one where hype and evidence diverge most. Here is what has actually reached human trials, and what has not.